CXCR4 and colorectal carcinoma: We, next assessed T22‐GFP‐H6‐FdU capacity to prevent LN, LV, LG, and PTN Mets development in the CXCR4+ M5 orthotopic CRC model, which shows higher metastatic efficiency at all sites (Table 1).